Neuroprotective properties of GLP-1: Theoretical and practical applications

Current Medical Research and Opinion

Volumn 27, Issue 3, 2011, Pages 547-558

  Holst, Jens Juul ^a   Burcelin, Remy ^b   Nathanson, Esther ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rangueil Institute of Molecular Medicine   (France)

^c Watermeadow Medical USA   (United States)

Author keywords

Alzheimer's disease; GLP 1; Huntington'sdisease; Neurodegenerative; Parkinson's disease; Protection

Indexed keywords

CYCLIC AMP; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LEVODOPA; LIRAGLUTIDE; METFORMIN; NERVE GROWTH FACTOR; SITAGLIPTIN;

ALZHEIMER DISEASE; APOPTOSIS; BLOOD GLUCOSE MONITORING; ENCEPHALITIS; HEART PROTECTION; HUMAN; HUNTINGTON DISEASE LIKE SYNDROME; MEMORY DISORDER; MOTOR COORDINATION; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NERVE CONDUCTION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; DIABETES COMPLICATIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS;

EID: 79951626557     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.549466     Document Type: Review

References (141)

1. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206 (Pubitemid 38943883)
2. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes 1989;38:902-5 (Pubitemid 20022397)
3. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123: 2009-13
4. Jin SL, Han VK, Simmons JG, et al. Distribution of glucagon-like peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988;271:519-32
5. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52 (Pubitemid 34743464)
6. Knauf C, Cani PD, Kim DH, et al. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 2008;57:2603-12
7. Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997;77:257-70 (Pubitemid 27060323)
8. Zueco JA, Esquifino AI, Chowen JA, et al. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36) amide on vasopressin and oxytocin release. J Neurochem 1999;72:10-6 (Pubitemid 29013872)
9. Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996;271:R848-56
10. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998;274:R23-9
11. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72 (Pubitemid 26008136)
12. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005;115:3554-63 (Pubitemid 43121843)
13. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20 (Pubitemid 28084232)
14. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-87
15. Burcelin R, Serino M, Cabou C. A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. Curr Opin Pharmacol 2009;9:744-52
16. Orskov C, Poulsen SS, Moller M, et al. Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996;45:832-5 (Pubitemid 26168585)
17. Bucinskaite V, Tolessa T, Pedersen J, et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009;21:978-e78
18. Williams DL. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009;150:2997-3001
19. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992;89:8641-5
20. Perry TA, WeerasuriyaA, Mouton PR, etal. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol 2004;190:133-44 (Pubitemid 39335713)
21. Green B, Gault V Flatt P, etal. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004;428:136-43 (Pubitemid 38891556)
22. Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4 (Pubitemid 36115169)
23. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50 (Pubitemid 351653542)
24. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-31
25. Perry TA, Greig N. A new Alzheimer's disease interventive strategy: GLP-1 Current Drug Targets 2004;5:565-71 (Pubitemid 39004431)
26. Perry TA, Haughey N, Mattison M, et al. Protection and reversal of excitotxic neuronal damage by glucagon-like peptide-1 and exendin 4. J Pharmacol Exp Ther 2002;302:881-8 (Pubitemid 34920207)
27. Navarro M, de Fonseca R, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996;67:1982-91 (Pubitemid 26349672)
28. Goke R, Larsen PJ, Mikkelsen JD, et al. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300
29. Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43 (Pubitemid 47604973)
30. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398-405
31. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Molecular Endocrinology 2003;17:161-71 (Pubitemid 36183142)
32. Stoffers DA, KiefferTJ, HussainMA, etal. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741-8 (Pubitemid 30339989)
33. During M, Cao L, Zuzga D, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 2003;9:1173-9 (Pubitemid 37173702)
34. Perry TA, Lahiri D, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-^ peptide (Ap) levels and protects hippocampal neurons from death induced by Ap and iron. J Neurosci Res 2003;72:603-12 (Pubitemid 36578646)
35. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158-62
36. McClean PL, Abbas T, Faivre E, et al. Impairment of synaptic plasticity and learning in GLP-1 receptor knockout mice: interaction between type 2 diabetes and Alzheimer's Disease. Diabetologia 2009;52(Suppl 1):S109 (abstract 252)
37. Young D, Lawlor PA, Leone P, et al. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 1999;5:448-53 (Pubitemid 29180587)
38. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci 2001;24:700-5 (Pubitemid 33097536)
39. European Medicines Agency Scientific Discussion of exenatide. London, UK: European Medicines Agency, 2006. Available at http://www.ema.europa.eu/ humandocs/PDFs/EPAR/byetta/H-698-en6.pdf [Last accessed 8 July 2010]
40. ParkesD, JodkaC, Smith P, etal. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001;54:260-7 (Pubitemid 33029654)
41. Byetta® prescribing information. Indianapolis, IN: Eli Lilly and Company,2009. Available at http://pi.lilly.com/us/byetta-pi.pdf [Last accessed 8 July 2010]
42. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27:313-18 (Pubitemid 36384867)
43. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-9
44. Elbrønd B, Jakobsen G, Larsen S, etal. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting gluca-gon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404 (Pubitemid 41071152)
45. Victoza® Prescribing information. Bagsvaerd, Denmark: Novo Nordisk A/S, 2010. Available athttp://www.victoza.com/pdf/PI-(1-Column-Format).pdf [Last accessed 8 July 2010]
46. Gonzalez C, Beruto V, Keller G, et al. Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Invest Drugs 2006;15:887-95 (Pubitemid 44177842)
47. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med. 2009;76(Suppl 5):S4-11
48. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463-77
49. Orskov C, Poulsen SS, Møller M, et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996;45:832-5 (Pubitemid 26168585)
50. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol 2010;92:442-62
51. Baraboi ED, Smith P, Ferguson AV, et al. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 2010;298:R1098-110
52. Vrang N, Jelsing J, Raun K, et al. Liraglutide regulates key hypothalamic appetite-related signals in diet-induced obese rats. Diabetes 2010;59(Suppl 1):A159 (abstract 583-P)
53. Raun K, Vrang N, Jelsing J, et al. The GLP-1 analog liraglutide activates brainstem and hypothalamic neurons involved in appetite regulation. Diabetes 2010;59(Suppl 1):A159 (abstract 584-P)
54. Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptiylpeptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
55. Pratley R, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
56. McGill J. Liraglutide: effects beyond glycaemic control in diabetes treatment. Int J Clin Pract 201064:28-34
57. Hjøllund KR, HughesTE, Deacon CF, etal. The dipeptidyl peptidase-4 inhibitor vildagliptin increases portal concentrations of active GLP-1 to a greater extent that the peripheral concentrations. Diabetologia 2008;57:A411
58. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14 (Pubitemid 34252619)
59. Hölscher C, Fung K, McCurtin R, et al. Novel GLP-1 analogues can cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's Disease. Diabetologia 2009;52(Suppl 1):S311 (abstract 790)
60. Nystrom T, Gonon AT, Sjoholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005;125:173-7 (Pubitemid 39593722)
61. Green BD, Hand KV, Dougan JE, et al. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008;478:136-42
62. Hardikar AA, Wang XY, Williams LJ, et al. Functional maturation of fetal porcine j6-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 2002;143:3505-14 (Pubitemid 34925725)
63. Movassat J, Beattie GM, Lopez AD, et al. Exendin 4 up-regulates expression of PDX1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 2002;87:4775-81 (Pubitemid 35247075)
64. Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143:3152-61 (Pubitemid 34809888)
65. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-8 (Pubitemid 26375413)
66. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66 (Pubitemid 34165002)
67. Luciani P, Deledda C, Benvenuti S, et al. Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model. Cell Mol Life Sci 2010;67:3711-23
68. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Eur J Intern Med 2009;20(Suppl 2):S319-28
69. Grieve D, Cassidy R, Green B. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic actions beyond glycaemic control. Br J Pharmacol 2009;157:1340-51
70. Tourrel C, Bailbe D, Lacorne M, et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the /S-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002;51:1443-52 (Pubitemid 34826610)
71. Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose intolerant rats. Endocrinology 2000;141:4600-5 (Pubitemid 32055138)
72. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52
73. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008;86:326-38 (Pubitemid 351196738)
74. Belsham D, Fick L, Dalvi P, et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J 2009;23: 4256-65
75. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61 (Pubitemid 39128621)
76. Nikolaidis LA, Mankad S, Sokos GG, etal. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5 (Pubitemid 38282847)
77. Abu-Hamdah R, Rabiee A, Meneilly G, et al. The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843-52
78. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408 (Pubitemid 35239574)
79. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002;45:1263-73
80. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-15 (Pubitemid 38756992)
81. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-8 (Pubitemid 36043598)
82. Cornu M, Modi H, Kawamori D, et al. Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem 2010;285: 10538-45
83. Cornu M, Yang JY, Jaccard E, et al. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 2009;58:1816-25
84. Ferdaoussi M, Abdelli S, Yang JY, et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008;57:1205-15
85. Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 2008;34(Suppl 2):S49-55
86. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434-8 (Pubitemid 17085418)
87. Kreymann B, Ghatei MA, Williams G, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4 (Pubitemid 17156636)
88. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999;48:2358-66 (Pubitemid 30395427)
89. Bjerre Knudsen L, Tang-Christensen M, Jelsing J, et al. Liraglutide: shortlived effect on gastric emptying, long-lasting effects on body weight. Diabetes 2010;59(Suppl 1):A161 (abstract 591-P)
90. Li Y, Tweedie D, Mattson MP, et al. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 2010;113:1621-31
91. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose response, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-32
92. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87: 1239-46 (Pubitemid 36121094)
93. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006;73:142-50 (Pubitemid 44155916)
94. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61 (Pubitemid 38766408)
95. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003;23: 2939-46 (Pubitemid 36418630)
96. Gilman CP, Mattson MP. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? Neuromolecular Med 2002;2:197-214 (Pubitemid 37012504)
97. Mattson MP, Dou P, Kater SB. Outgrowth-regulating actions of glutamate in isolated hippocampal pyramidal neurons. J Neurosci 1988;8:2087-100
98. Mattson MP, Lee RE, Adams ME, et al. Interactions between entorhinal axons and target hippocampal neurons: a role for glutamate in the development of hippocampal circuitry. Neuron 1988;1:865-76
99. Greig N, Mattson M, Perry TA, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases. P53 and TNF-a inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004;1035:290-315 (Pubitemid 40362340)
100. Hö lscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 2008 doi:10.1016/j.neurobiolaging.2008.08.023
101. Li Y, Perry TA, Kindy M, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS 2009;106:1285-90
102. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004;3:169-78 (Pubitemid 38229951)
103. Luchsinger JA, Gustafson D. Adiposity, type 2 diabetes and Alzheimer's disease. J Alzheimers Dis 2009;16:693-704
104. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008;585: 119-29
105. Frautschy S, Cole G. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 2010;41:392-409
106. Beeri MS, Schmeidler J, Silverman JM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008;71:750-7
107. Sambamurti K, Greig N, Lahiri D. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002;1:1-31 (Pubitemid 37021521)
108. Jolivalt C, Lee C, Beiswenger K, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurisci Res 2008;86:3265-74
109. Xie L, Helmerhorst E, Taddei K, et al. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002;22:RC221
110. Zhao W, De Felice F, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. Faseb J 2008;22:246-60
111. Gault V, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008;587:112-17
112. Gao H, Wang X, Zhang Z, et al. GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 2007;32:90-5 (Pubitemid 350242552)
113. Li Y, Duffy K, Ottinger M, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010;19:1205-19
114. Gengler S, McClean PL, McCurtin R, et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010; doi:10.1016/j.neurobiolaging.2010.02.014
115. D'Amico M, Di Filippo C, Marfella R, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010;45:202-7
116. Asmar M, Højberg PV, Deacon CF, et al. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regul Pept 2010;160:175-80
117. Irwin, N, Clarke G, Green B, et al. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol 2006;72:719-28 (Pubitemid 44233552)
118. Gandhi S, Wood N. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005;14:2749-55 (Pubitemid 41300647)
119. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Neurosci 2007;8:57-69 (Pubitemid 46011999)
120. Whitton P. Inflammation as a potential causative factor in the aetiology of Parkinsons disease. Br J Pharmacol 2007;150:963-76 (Pubitemid 46628616)
121. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76 (Pubitemid 351441488)
122. Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 2010;16(Suppl Implications):S87-93
123. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6 (Pubitemid 46184217)
124. Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30:842-7 (Pubitemid 46562366)
125. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation abd matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 2009;202:431-9
126. Kim Chung le T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009;390:613-18
127. Dozier KC, Cureton EL, Kwan RO, et al. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009;30:1735-41
128. Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008;21;5:19
129. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004;5:958-63 (Pubitemid 39534452)
130. Spinney L. Uncovering the true prevalence of Huntington's disease. Lancet Neurol 2010; doi:10.1016/S1474-4422(10)70160-5
131. Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntingdon's disease. Diabetes 2009;58:318-28
132. Aziz N, Swaab D, Pijl H, et al. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007;18:223-51
133. Hunt M, Morton A. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's Disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 2005;166:220-9 (Pubitemid 41406813)
134. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006456
135. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006455
136. Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care 2007;30: 3131-40 (Pubitemid 350258454)
137. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007;6:337-50
138. Noyan-Ashraf M, Momen M, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83
139. Perry TA, Holloway H, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301 (Pubitemid 46157226)
140. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004;110:36-43 (Pubitemid 38180536)
141. Burcelin R, Da Costa A, Drucker D, et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001;50:1720-8 (Pubitemid 33641588)